March 16, 2018 / 11:23 PM / 2 years ago

Stemline Therapeutics wins dismissal of shareholder lawsuit

A federal judge has dismissed a lawsuit accusing Stemline Therapeutics Inc of misleading investors about its ability to address the risk of a fatal side effect associated with a drug it was developing to treat certain blood-related cancers.

U.S. District Judge Paul Crotty in Manhattan wrote that contrary to the investors’ claims, a prospectus Stemline issued in 2017 made clear that the company never claimed it could eliminate the risk of the side effect developing.

To read the full story on Westlaw Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below